Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 6/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22352187 | 0.90 | TGM2 (0.59) | FUT5TGM2NT5EPOLBKRAS | |
| SCHEMBL23679806 | 0.89 | NT5E (0.55) | FUT5TGM2NT5EPOLBKRAS | |
| SCHEMBL20762967 | 0.84 | POLB (0.54) | FUT5TGM2NT5EPOLBKRAS | |
| SCHEMBL20762962 | 0.84 | POLB (0.54) | FUT5TGM2NT5EPOLBKRAS | |
| SCHEMBL14659957 | 0.82 | NT5E (0.77) | FUT5TGM2NT5EKRASP2RY2 | |
| SCHEMBL29160869 | 0.82 | NT5E (0.77) | FUT5TGM2NT5EKRASP2RY2 | |
| SCHEMBL18258303 | 0.82 | NT5E (0.77) | FUT5TGM2NT5EKRASP2RY2 | |
| SCHEMBL25552773 | 0.82 | TGM2 (0.60) | FUT5TGM2NT5EPOLBKRAS | |
| SCHEMBL17461710 | 0.82 | TGM2 (0.54) | FUT5TGM2NT5EPOLBKRAS | |
| SCHEMBL22475042 | 0.82 | FUT5 (0.64) | FUT5TGM2NT5EPOLBKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799524-B2 | Methods for treating hepatitis B infection | DICERNA PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200171069-A1 | METHODS FOR TREATING HEPATITIS B INFECTION | DICERNA PHARMACEUTICALS, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171069-A1 | METHODS FOR TREATING HEPATITIS B INFECTION | HAVCR2, HDGF, FABP1 | FUT5 1019/4885TGM2 605/4885NT5E 1009/4885 |
| US-10799524-B2 | Methods for treating hepatitis B infection | HAVCR2, HDGF, FABP1 | FUT5 1019/4885TGM2 605/4885NT5E 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.